HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy - Kemp, Steven A.; Charles, Oscar; Derache, Anne; Iwuji, Collins; Adamson, John; Govender, Katya; de Oliveira, Tulio; Okesola, Nonhlanhla; Dabis, Francois; Martin, Darren P.; on behalf of the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group; Pillay, Deenan; et al. (medRxiv, 2021)
Viral population dynamics in long term viraemic antiretroviral therapy (ART) treated individuals have not been well characterised. Prolonged virologic failure on 2nd-line protease inhibitor (PI) based ART without emergence of major protease mutations is well recognised, providing an opportunity to study within-host evolution.Using next-generation Illumina short read sequencing and in silico haplotype reconstruction we analysed whole genome sequences from longitudinal plasma samples of eight chronically infected HIV-1 individuals failing 2nd-line regimens from the ANRS 12249 TasP trial, in the absence of high frequency major PI resistance mutations. Plasma drug levels were measured by HPLC. Three participants were selective for in-depth variant and haplotype analyses, each with five or more timepoints spanning at least 16 months. Recombination and linkage disequilibrium between haplotypes and genes was also explored.During PI failure synonymous mutations were around twice as frequent as non-synonymous mutations across participants. Prior to or during exposure to PI, we observed several polymorphic amino acids in gag (e.g. T81A, T375N) which are have also been previously associated with exposure to protease inhibitor exposure. Although overall SNP frequency at abundance above 2% appeared stable across time in each individual, divergence from the consensus baseline sequence did increase over time. Non-synonymous changes were enriched in known polymorphic regions such as env whereas synonymous changes were more often observed to fluctuate in the conserved pol gene. Phylogenetic analyses of whole genome viral haplotypes demonstrated two common features: Firstly, evidence for selective sweeps following therapy switches or large changes in plasma drug concentrations, with hitchhiking of synonymous and non-synonymous mutations. Secondly, competition between multiple viral haplotypes that intermingled phylogenetically alongside soft selective sweeps. The diversity of viral populations was maintained between successive timepoints with ongoing viremia, particularly in env. Changes in haplotype dominance were often distinct from the dynamics of drug resistance mutations in reverse transcriptase (RT), indicating the presence of softer selective sweeps and/or recombination.Large fluctuations in variant frequencies with diversification occur during apparently ‘stable’ viremia on non-suppressive ART. Reconstructed haplotypes provided further evidence for sweeps during periods of partial adherence, and competition between haplotypes during periods of low drug exposure. Drug resistance mutations in RT can be used as markers of viral populations in the reservoir and we found evidence for loss of linkage disequilibrium for drug resistance mutations, indicative of recombination. These data imply that even years of exposure to PIs, within the context of large stable populations displaying ongoing selective competition, may not precipitate emergence of major PI resistance mutations, indicating significant fitness costs for such mutations. Ongoing viral diversification within reservoirs may compromise the goal of sustained viral suppression.Competing Interest StatementRKG has received ad hoc consulting fees from Gilead, ViiV and UMOVIS Lab.Clinical TrialClinicaltrials.gov: NCT01509508Funding StatementSAK is supported by the Bill and Melinda Gates Foundation: OPP1175094. RKG is supported by Wellcome Trust Senior Fellowship in Clinical Science: WT108082AIA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was originally grant by the Biomedical Research Ethics Committee (BFC 104/11) at the University of KwaZulu-Natal, and the Medicines Control Council of South Africa for the TasP trial (Clinicaltrials.gov: NCT01509508; South African Trial Register: DOH-27-0512-3974). The study was also authorized by the KwaZulu-Natal Department of Health in South Africa. Written informed consent was obtained from all participants. Original ethical approval also included downstream sequencing of blood plasma samples and analysis of those sequences to better understand drug resistance. No additional ethical approval was required for this.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data has been provided as supplementary tables. Sequencing data can be provided upon reasonable request to the authors.